Roche valganciclovir
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA Antiviral Drugs Advisory Committee will review valganciclovir 450 mg tablets for the treatment of cytomegalovirus retinitis in patients with AIDS Feb. 27. Valganciclovir is a pro-drug of Roche's existing anti-CMV retinitis treatment Cytovene (ganciclovir